[go: up one dir, main page]

AU2002228745A1 - Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma - Google Patents

Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma

Info

Publication number
AU2002228745A1
AU2002228745A1 AU2002228745A AU2874502A AU2002228745A1 AU 2002228745 A1 AU2002228745 A1 AU 2002228745A1 AU 2002228745 A AU2002228745 A AU 2002228745A AU 2874502 A AU2874502 A AU 2874502A AU 2002228745 A1 AU2002228745 A1 AU 2002228745A1
Authority
AU
Australia
Prior art keywords
antibodies
production
directed against
interferon gamma
ligands directed
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2002228745A
Inventor
Eric O. Long
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
RAJAGOPALAN SUMATI
US Department of Health and Human Services
Original Assignee
US Department of Health and Human Services
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by US Department of Health and Human Services filed Critical US Department of Health and Human Services
Publication of AU2002228745A1 publication Critical patent/AU2002228745A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G01N2333/70503—Immunoglobulin superfamily, e.g. VCAMs, PECAM, LFA-3
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/02—Screening involving studying the effect of compounds C on the interaction between interacting molecules A and B (e.g. A = enzyme and B = substrate for A, or A = receptor and B = ligand for the receptor)

Landscapes

  • Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
AU2002228745A 2000-10-23 2001-10-23 Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma Abandoned AU2002228745A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24241900P 2000-10-23 2000-10-23
US60/242,419 2000-10-23
PCT/US2001/046098 WO2002034290A2 (en) 2000-10-23 2001-10-23 Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma

Publications (1)

Publication Number Publication Date
AU2002228745A1 true AU2002228745A1 (en) 2002-05-06

Family

ID=22914715

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2002228745A Abandoned AU2002228745A1 (en) 2000-10-23 2001-10-23 Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma

Country Status (3)

Country Link
US (2) US7435801B2 (en)
AU (1) AU2002228745A1 (en)
WO (1) WO2002034290A2 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10261223A1 (en) * 2002-12-20 2004-07-08 MedInnova Gesellschaft für medizinische Innovationen aus akademischer Forschung mbH Increasing the immune response through substances that influence the function of natural killer cells
LT1648507T (en) * 2003-07-24 2017-04-25 Innate Pharma S.A. Methods and compositions for increasing the efficiency of therapeutic antibodies using nk cell potentiating compounds
EP2641611A3 (en) * 2003-10-17 2013-12-18 Novo Nordisk A/S Combination therapy
SI1836225T1 (en) * 2005-01-06 2012-06-29 Novo Nordisk As Kir-binding agents and methods of use thereof
KR20170091801A (en) 2008-10-02 2017-08-09 압테보 리서치 앤드 디벨롭먼트 엘엘씨 CD86 Antagonist Multi-Target Binding Proteins
TW201829463A (en) 2016-11-18 2018-08-16 瑞士商赫孚孟拉羅股份公司 anti-HLA-G antibody and use thereof
AR114789A1 (en) 2018-04-18 2020-10-14 Hoffmann La Roche ANTI-HLA-G ANTIBODIES AND THE USE OF THEM
AR115052A1 (en) 2018-04-18 2020-11-25 Hoffmann La Roche MULTI-SPECIFIC ANTIBODIES AND THE USE OF THEM
CA3204702A1 (en) 2020-12-17 2022-06-23 F. Hoffmann-La Roche Ag Anti-hla-g antibodies and use thereof
JP2024521185A (en) * 2021-05-26 2024-05-28 ボード オブ リージェンツ，ザ ユニバーシティ オブ テキサス システム Chimeric antigen receptor targeting HLA-G positive cancer
EP4352232A4 (en) * 2021-06-09 2025-05-21 Serotiny, Inc. SYNTHETIC RECEPTOR FOR CONDITIONAL ACTIVATION OF IMMUNE CELLS
CN117448412A (en) * 2022-07-26 2024-01-26 中山大学孙逸仙纪念医院 CD158d molecules, neutralizing antibodies, and applications
EP4680638A1 (en) 2023-03-13 2026-01-21 F. Hoffmann-La Roche AG Treatment of cancer using an anti-hla-g/anti-cd3 bispecific antibody and a 4-1bb (cd137) agonist
EP4680635A1 (en) 2023-03-13 2026-01-21 F. Hoffmann-La Roche AG Combination therapy employing a pd1-lag3 bispecific antibody and an hla-g t cell bispecific antibody

Also Published As

Publication number Publication date
US20030232051A1 (en) 2003-12-18
US7435801B2 (en) 2008-10-14
US20100255507A1 (en) 2010-10-07
WO2002034290A2 (en) 2002-05-02
WO2002034290A9 (en) 2003-05-30
WO2002034290A3 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
AU1795901A (en) "bonzo" chemokine receptor antibodies and ligands
IL201751A (en) Il-17 like cytokine binding compound and antibodies
AU1462300A (en) Human pan-hcv human monoclonal antibodies
EP1110086A4 (en) Production of motif-specific and context-independent antibodies using peptide libraries as antigens
AU1290001A (en) Antibodies
HUP0100794A3 (en) Novel method for the production of anti-human antigen receptors and uses thereof
SI1406656T1 (en) Methods of administering anti-tnf-alpha antibodies
AU4314900A (en) Parenteral medicinal composition containing humanized monoclonal antibody fragment and method for stabilizing the same
GB0029360D0 (en) Humanised antibodies and uses thereof
AU2002228745A1 (en) Antibodies and other ligands directed against kir2dl4 receptor for production of interferon gamma
AU2002340167A1 (en) Anti-hla-dr antibodies and the methods of using thereof
AU4935000A (en) Antibodies
AU2001292867A1 (en) Ligands for g protein coupled receptors and methods of using them
AU2001256325A1 (en) Human and humanized fap-alpha-specific antibodies
GB9927332D0 (en) Novel antibody and uses thereof
AU6618100A (en) Monoclonal antibodies to tacrolimus and immunoassay methods for tacrolimus
AU2002305478A1 (en) Conjugates of reduced antibodies and biomolecules
AU5441000A (en) Human monoclonal antibody
AUPR546801A0 (en) Recombinant antibodies
AU2003260513A1 (en) Polyclonal antibodies, preparation method thereof and use of same
AU2002341839A1 (en) Monoclonal antibodies to the drug tilmicosin and a method for detecting the same
AU2003299929A1 (en) System for production and screening of monoclonal antibodies
AU2452301A (en) Protein methylarginine-specific antibodies
HUP0202270A3 (en) Antitumor antibodies, proteins, and uses thereof
AU2001284454A1 (en) Method of screening antitumor agent by using interaction between arf protein and hk33 protein